Overview

A Study of LY2334737 in Participants With Cancer That is Advanced and/or Has Spread

Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate two different dosing regimens of LY2334737 in participants with cancer that is advanced and/or has spread to other parts of the body. Information about side effects will be collected.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Deoxyuridine